EUVIMEDEUVIMED entdecken
Crossref

Chelating [ 227 Th]Th 4+ for Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors

Luke Wharton iD, Scott W McNeil, Harrison Meeres, Diduo Zhang, Aidan Ingham, Helen Merkens, Maryam Osooly, Cristina Rodríguez-Rodríguez iD, François Bénard iD, Hua Yang iD

Bioconjugate Chemistry · 2025

DOI: 10.1021/acs.bioconjchem.5c00129 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2025. Verfasst von Luke Wharton und 9 weiteren Autor:innen. Beteiligte Einrichtung: Life Sciences Division, TRIUMF, Vancouver, British Columbia V6T 2A3, Canada. Hauptthemen laut MEDLINE: Thorium, Chelating Agents, Neuroendocrine Tumors, Receptors, Peptide. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Canadian Institutes of Health Research, National Research Council Canada, Natural Sciences and Engineering Research Council of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted alpha therapy (TAT) has shown high promise for the effective treatment of advanced stage cancers. Of the proposed radionuclides for TAT, Thorium-227 represents an interesting candidate given its relatively long half-life, 18.7 days, and the cascade of short-lived, high-potency, alpha-emitting daughter progeny in its decay scheme. However, to date few chelators exist which can effectively and stably bind [227Th]Th4+ at molar activities high enough for TAT. To address this challenge, this study investigated various chelating ligands for coordination of [227Th]Th4+. H4noneunpaX was identified as a promising chelator, demonstrating radiolabeling with [227Th]Th4+ at concentrations of 10-6 M (Am = 272 kBq/nmol). The coordination characteristics of [Th(noneunpaX)] have been investigated through 1H NMR spectroscopy, mass spectrometry, and DFT calculations. In this study, we also investigate for the first time the pairing of Th-227 with a peptide-based bioconjugate and evaluate the in vivo biodistribution characteristics. [227Th]Th-nonenupaX-Ahx-Tyr3-TATE was prepared under mild conditions (ambient temperature, 30 min) and evaluated in NRG mice bearing AR42J xenografts as a model for pancreatic neuroendocrine tumors. The 227Th-labeled radiopeptide showed high uptake in tumors (25.8±6.2 %IA/g at 3 h p.i.) and low uptake in non-targeted organs. Although some release of Th-227 was noted in serum stability studies this was not observed in vivo. This ligand architecture serves as an interesting framework for future optimization, which will involve improvements to the overall stability by enhancing the rigidity of the backbone and assessing other pendent donor groups with a stronger affinity toward [227Th]Th4+. Overall, this study demonstrated for the first time the viability of using peptide-based targeting to effectively deliver Th-227 to tumor sites.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThoriumChelating AgentsNeuroendocrine TumorsReceptors, PeptideRadiopharmaceuticalsAnimalsHumansMiceTissue DistributionCell Line, Tumor

Substanzen

ThoriumChelating AgentsThorium-227Receptors, PeptideRadiopharmaceuticals

Autor:innen und Institutionen

  • Life Sciences Division, TRIUMF, Vancouver, British Columbia V6T 2A3, Canada.
  • Department of Chemistry, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada.
  • Interdisciplinary Oncology Program, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada.
  • Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, British Columbia V5Z 1L3, Canada.
  • Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada.
  • Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada.

ORCID-Profile: Luke Wharton, Cristina Rodríguez-Rodríguez, François Bénard, Hua Yang

Förderung

  • Canadian Institutes of Health Research
  • National Research Council Canada
  • Natural Sciences and Engineering Research Council of Canada

Zitieren

APA

Wharton, L., McNeil, S. W., Meeres, H., Zhang, D., Ingham, A., Merkens, H., Osooly, M., Rodríguez-Rodríguez, C., Bénard, F., & Yang, H. (2025). Chelating [ 227 Th]Th 4+ for Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00129

Vancouver

Wharton L, McNeil SW, Meeres H, Zhang D, Ingham A, Merkens H, et al. Chelating [ 227 Th]Th 4+ for Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors. Bioconjugate Chemistry. 2025. doi:10.1021/acs.bioconjchem.5c00129

BibTeX
@article{Wharton2025,
  author = {Wharton, Luke and McNeil, Scott W and Meeres, Harrison and Zhang, Diduo and Ingham, Aidan and Merkens, Helen and Osooly, Maryam and Rodríguez-Rodríguez, Cristina and Bénard, François and Yang, Hua},
  title = {Chelating [ 227 Th]Th 4+ for Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors},
  journal = {Bioconjugate Chemistry},
  year = {2025},
  doi = {10.1021/acs.bioconjchem.5c00129}
}
Kostenlos starten →